Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 116

Similar articles for PubMed (Select 22232539)

1.

The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.

Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS.

BMJ. 2012 Jan 9;344:e42. doi: 10.1136/bmj.e42. Review.

2.

RAS blockade, hyperkalemia and AKI--look and you will find.

Toto RD.

Nat Rev Nephrol. 2012 May;8(5):257-8. doi: 10.1038/nrneph.2012.62.

PMID:
22473512
3.

No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

Gilbert CJ, Gomes T, Mamdani MM, Hellings C, Yao Z, Garg AX, Wald R, Harel Z, Juurlink DN.

Can J Cardiol. 2013 May;29(5):586-91. doi: 10.1016/j.cjca.2013.02.015. Epub 2013 Mar 29.

4.

Combination antihypertensive treatment with aliskiren and blockers of the Renin-Angiotensin system-reassurance but with a note of caution.

Touyz RM.

Can J Cardiol. 2013 May;29(5):521-3. doi: 10.1016/j.cjca.2013.02.020. Epub 2013 Mar 29. No abstract available.

PMID:
23541659
5.

Dual renin-angiotensin system blockade.

de Leeuw PW.

BMJ. 2012 Feb 1;344:e656. doi: 10.1136/bmj.e656. No abstract available.

PMID:
22297794
6.

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A.

Hypertension. 2007 Feb;49(2):276-84. Epub 2006 Dec 11.

7.

Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.

Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH.

BMJ. 2013 Jan 28;346:f360. doi: 10.1136/bmj.f360. Review.

8.

Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.

Chrysant SG, Murray AV, Hoppe UC, Dattani D, Patel S, Hsu H, Zhang J.

Curr Med Res Opin. 2008 Apr;24(4):1039-47. doi: 10.1185/030079908X280581 . Epub 2008 Feb 27.

PMID:
18307835
9.

Direct renin inhibitor induced renal failure.

Vallakati A, Chandra PA, Hollander G, Shani J.

Am J Ther. 2014 Mar-Apr;21(2):e53-5. doi: 10.1097/MJT.0b013e3182459c16.

PMID:
23665882
10.

Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.

White WB, Bresalier R, Kaplan AP, Palmer BF, Riddell RH, Lesogor A, Chang W, Keefe DL.

J Clin Hypertens (Greenwich). 2011 Jul;13(7):506-16. doi: 10.1111/j.1751-7176.2011.00438.x. Epub 2011 Mar 18.

PMID:
21762364
11.

Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren.

Sepehrdad R, Frishman WH, Stier CT Jr, Sica DA.

Cardiol Rev. 2007 Sep-Oct;15(5):242-56. Review.

PMID:
17700383
12.

A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension.

Zhenfeng Zheng, Huilan Shi, Junya Jia, Dong Li, Shan Lin.

J Renin Angiotensin Aldosterone Syst. 2011 Jun;12(2):102-12. doi: 10.1177/1470320310381912. Epub 2010 Nov 8. Review.

PMID:
21059822
13.

Aliskiren: a new inhibitor of renin-angiotensin aldosterone system activity.

Dalla Vestra M, Simioni N, Masiero A.

Minerva Endocrinol. 2009 Dec;34(4):333-8. Review.

PMID:
20046162
14.

Blood pressure lowering efficacy of renin inhibitors for primary hypertension: a Cochrane systematic review.

Musini VM, Fortin PM, Bassett K, Wright JM.

J Hum Hypertens. 2009 Aug;23(8):495-502. doi: 10.1038/jhh.2008.162. Epub 2009 Jan 22. Review.

PMID:
19158826
15.
16.

Aliskiren monotherapy does not cause paradoxical blood pressure rises: meta-analysis of data from 8 clinical trials.

Stanton AV, Gradman AH, Schmieder RE, Nussberger J, Sarangapani R, Prescott MF.

Hypertension. 2010 Jan;55(1):54-60. doi: 10.1161/HYPERTENSIONAHA.109.135772. Epub 2009 Nov 16.

17.

Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy.

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlöf B; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators.

Circulation. 2009 Feb 3;119(4):530-7. doi: 10.1161/CIRCULATIONAHA.108.826214. Epub 2009 Jan 19.

18.

Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions.

Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Garofoli M, Ramundo E, Biadetti A, Verdecchia P.

Curr Drug Saf. 2012 Feb;7(1):76-85. Review.

PMID:
22663961
19.

Aliskiren: an oral direct renin inhibitor for the treatment of hypertension.

Sanoski CA.

Pharmacotherapy. 2009 Feb;29(2):193-212. doi: 10.1592/phco.29.2.193. Review.

PMID:
19170589
20.

In brief: aliskiren trial terminated.

[No authors listed]

Med Lett Drugs Ther. 2012 Jan 23;54(1382):5. No abstract available.

PMID:
22267213
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk